BUZZ-Allarity more than doubles on US FDA's 'fast track' tag for ovarian cancer therapy

Reuters
08/26
BUZZ-Allarity more than doubles on US FDA's 'fast track' tag for ovarian cancer therapy

Updates

** Shares of drug developer Allarity Therapeutics ALLR.O rise 132% to over 10-month high of $2.19

** Stock set for its biggest one-day pct gain on record, if gains hold

** Co says U.S. FDA granted fast track designation to its experimental ovarian cancer therapy, stenoparib

** Stenoparib, an oral drug, works by blocking two enzymes that cancer cells use to repair themselves and keep growing

** FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical need

** The therapy was originally developed by Japan's Eisai 4523.T and later licensed to Allarity, which secured global rights to develop and commercialize the drug

** As of last close, stock down 20% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10